Home > News Center
 
Contact Us
Shanghai BravoBio Co., Ltd.
Add:Suite 14E, Building #5, Haifu Garden, 1365 Dongfang Road, Lujiazui Financial and Trade Zone, Shanghai 200127, China
Tel: +86 21 2025 5516
Fax: +86 21 2025 5517
Email: bd@bravobio.com
News Center
 
IVI wants to deepen ties with India for vaccines
Aug. 31, 2013
 
The South Korea-based non-profit organization, International Vaccine Institute (IVI), said it is looking to deepen its engagement with India for clinical development and manufacturing of typhoid fever, shigellosis and dengue vaccines, according to the report from Hindustan Times.
 
BravoBio attended World Biopharma Week China Focus 2013
Sep. 6, 2013
 
The BD Director, Xiaoshu Zhang, was invited as speaker in the conference held in Best Western Pudong Sunshine Hotel, Shanghai. Her speech was Reduce the gap between China and Western World by bridging collaboration.
 
Four-strain nasal spray vaccine receives positive opinion in EU
Sep. 24, 2013
 
Fluenz Tetra of AstraZeneca was backed by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). The nasally administered four-strain live attenuated influenza vaccine contains two strains of influenza A and two strains of influenza B to provide broad protection against influenza B in children.
 
BravoBio attended Vaccine World China 2013
Sep. 26, 2013
 
The Organized by IMAPAC Ltd., the summit attracted vaccine companies and institutions from Asia, Europe and the States.Invited as a keynote speaker, Dr. Wu Ke shared with the audience BravoBio's experiences of international collaboration. He also moderated a panel discussion on comparison of different cell types in vaccine production.
 
EMA will publishes minutes of its committees
Oct. 8, 2013
 
EMA agreed to publish the agendas and minutes of its scientific committees, including Committee for Medicinal Products for Human Use (CHMP), Committee for Advanced Therapies (CAT), and Committee for Medicinal Products for Veterinary use (CVMP). This is part of the EMA's approach to increasing transparency and opening up its operations. The agendas and minutes will be published by the end of the year.
 
Made-in-China vaccine prequalified by WHO
Oct. 13, 2013
 
On October 9, 2013, the World Health Organization (WHO) notified CFDA that the attenuated Japanese encephalitis vaccine produced by Chengdu Institute of Biological Products Co., Ltd. was added to its list of prequalified medicines. This is the first Chinese-produced vaccine prequalified by WHO.
 
FDA will enhance inspections in India
Oct. 24, 2013
 
The US regulator has expanded its inspection team to 19 in India and opened two more offices in Hyderabad and Mumbai, in addition to its first office in New Delhi. FDA plans to follow the same system of facility inspections in India that it already does in the US or other developed countries, including an aggressive surveillance and surprise inspections of manufacturing sites.
 
Novartis opened a new vaccine R&D lab in North Carolina
Oct. 29, 2013
 
Since the last vaccine R&D center in Holly Springs, NC, in 2008, Novartis has recently opened a new vaccine R&D lab in North Carolina, which will give Novartis R&D capacity for pipeline products, such as the HIV vaccine that is co-developed by Novartis and National Institutes of Health (NIH). Novartis plans to grow its headcount to 100.
 
Researchers developed new synthetic HIV protein needed for HIV-I vaccine
Oct. 29, 2013
 
Researchers at Duke University and Memorial Sloan-Kettering Cancer Center have created a synthetic protein that could elicit the broadly neutralizing antibodies needed for an effective HIV-1 vaccine. The glycopeptide mimics vulnerable parts of the HIV outer coat and binds well to broadly neutralizing antibodies and to the receptors on na?ve B cells of the neutralizing antibodies.
Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 Next